RxDoctor Payments Data

Shelley Schendel, DO

Pulmonary Disease · Shelby Township, MINPI 1215050570

Payments from drug & device makers

$17,652in general payments, 2019–2025

Across 81 payments — averaging $217.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$16K
  • AstraZeneca$298
  • Johnson & Johnson$286
  • GSK$183
  • Sunovion Pharmaceuticals Inc.$130
  • Boehringer Ingelheim$110
  • plus $545 from 14 others

What the payments were for

  • Food & beverage$1,552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$17,652 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$234,104
Medicare patients
544
Services billed
2,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter439$527,834
XolairOmalizumab13$71,114
Breztri AerosphereBudesonide/Glycopyr/Formoterol69$59,996
Dupixent SyringeDupilumab14$53,379
Breo ElliptaFluticasone/Vilanterol44$30,303
Spiriva RespimatTiotropium Bromide31$30,196
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$24,917
Combivent RespimatIpratropium/Albuterol Sulfate18$20,417
Albuterol Sulfate HfaAlbuterol Sulfate290$18,202
SymbicortBudesonide/Formoterol Fumarate39$15,602
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$13,582
Tiotropium Bromide18$13,303
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$9,450
Spiriva HandihalerTiotropium Bromide14$8,987
Atrovent HfaIpratropium Bromide11$8,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$183$583,054522 claims
AstraZenecaBreztri Aerosphere, Symbicort, Airsupra$298$81,585121 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$110$64,19567 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Shelby Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →